Nivolumab: tested with established drugs
136 studies: they are given beside it. Page 2 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- SBRT as a Vaccination for Metastatic MelanomaWithdrawnNCT04042506Phase 2Report a problem
- A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in ChinaActive, not recruitingNCT04015778Phase 2Report a problem
- Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic CancerCompletedNCT03970252Early Phase 1Report a problem
- Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer PatientsActive, not recruitingNCT03921684Phase 2Report a problem
- A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal CarcinomaCompletedNCT03914443Phase 1Report a problem
- Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal CancerWithdrawnNCT03879811Phase 2Report a problem
- NADIM II: Neo-Adjuvant ImmunotherapyActive, not recruitingNCT03838159Phase 2Report a problem
- Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%Status unknownNCT03808480Phase 2Report a problem
- An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseWithdrawnNCT03770299Phase 2Report a problem
- Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract CancerWithdrawnNCT03768531Phase 2Report a problem
- Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT03749018Phase 2Report a problem
- Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaSuspendedNCT03704714Phase 1/2Report a problem
- A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerCompletedNCT03661320Phase 3Report a problem
- REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric CancerActive, not recruitingNCT03610711Phase 1/2Report a problem
- Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic TransplantTerminatedNCT03588936Phase 1Report a problem
- A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and NeckActive, not recruitingNCT03576417Phase 3Report a problem
- Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)Active, not recruitingNCT03544736Phase 1/2Report a problem
- Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)Status unknownNCT03542461Phase 3Report a problem
- Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma PatientsCompletedNCT03366272Phase 2/3Report a problem
- ASCT With Nivolumab in Patients With Multiple MyelomaActive, not recruitingNCT03292263Phase 1/2Report a problem
- Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasCompletedNCT03277924Phase 1/2Report a problem
- Nivolumab With Chemotherapy in Refractory MDSTerminatedNCT03259516Phase 1/2Report a problem
- A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.Active, not recruitingNCT03233152Phase 1/2Report a problem
- Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue SarcomasWithdrawnNCT03149120Phase 2Report a problem
- Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal CancerActive, not recruitingNCT03044613Phase 1Report a problem
- A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Active, not recruitingNCT03033914Phase 1/2Report a problem
- Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple MyelomaTerminatedNCT03023527Phase 1Report a problem
- Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaWithdrawnNCT03014804Phase 2Report a problem
- Study of Adjuvant ONO-4538 With Resected Gastric CancerCompletedNCT03006705Phase 3Report a problem
- Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaCompletedNCT03004833Phase 2Report a problem
- Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory NeuroblastomaActive, not recruitingNCT02914405Phase 1Report a problem
- Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck CancerCompletedNCT02764593Phase 1Report a problem
- Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)TerminatedNCT02423954Phase 1/2Report a problem
- A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced MelanomaWithdrawnNCT02400385Phase 2Report a problem
- Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by SurgeryActive, not recruitingNCT02210117Early Phase 1Report a problem
- Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558CompletedNCT01176461Phase 1Report a problem